Hypoglycaemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitus.
E R SeaquistL BlondeJ B McGillSimon R HellerD M KendallJ B BumpassF M PompilioM L GrantPublished in: Diabetic medicine : a journal of the British Diabetic Association (2019)
Participants using Technosphere Insulin experienced clinically non-inferior glycaemic control and lower hypoglycaemia rates across a range of HbA1c levels compared with participants receiving insulin aspart. ClinicalTrials.gov: NCT01445951.